The Role of Long Non-coding RNAs in Immunotherapy Resistance

46Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

T-cell-based immunotherapies, particularly immune checkpoint inhibitors, are promising treatments for various cancers. However, a large subset of patients develop primary or secondary resistance upon treatment. Although the detailed mechanisms remain unclear, immune escape via alterations in both cancer and tumor microenvironment has been identified as critical causes of immune resistance. Moreover, some long non-coding RNAs (lncRNAs), named as immune-related lncRNAs, have been recognized as regulators of immune cell-specific gene expression that mediate immune processes. These immune-related lncRNAs may play a vital role in immunotherapy resistance. Herein, we summarize current immune-related lncRNAs and their underlying roles in immune resistance to provide strategies for future research and therapeutic alternatives to overcome immunotherapy resistance.

Cite

CITATION STYLE

APA

Zhou, Y., Zhu, Y., Xie, Y., & Ma, X. (2019, November 28). The Role of Long Non-coding RNAs in Immunotherapy Resistance. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2019.01292

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free